Listed

Niagen Bioscience, Inc.

NAGENasdaqCIK 1386570HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$29.8mRevenue, Q2 FY2026, three months to 2026-06-30$29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 4, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$29.8mRevenue, Q2 FY2026, three months to 2026-06-30$29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure−4.3% on a year earlier
  • Gross margin64.8%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $19.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure−0.2 pts on a year earlier
  • Operating margin2.4%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $700.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure−7.9 pts on a year earlier
  • Net margin3.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $963.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure−8.4 pts on a year earlier
  • Diluted EPS$0.01Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure−75.0% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$29.8mGross margin 64.8%
Diluted EPS$0.01, Q2 FY2026
Niagen Bioscience, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m25.6Revenue, Q3 FY2024, three months to 2024-09-30$25.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figure29.1Revenue, Q4 FY2024, three months to 2024-12-31$29.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure30.5Revenue, Q1 FY2025, three months to 2025-03-31$30.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure31.1Revenue, Q2 FY2025, three months to 2025-06-30$31.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure34.0Revenue, Q3 FY2025, three months to 2025-09-30$34.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figure33.8Revenue, Q4 FY2025, three months to 2025-12-31$33.8m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure31.5Revenue, Q1 FY2026, three months to 2026-03-31$31.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure29.8Revenue, Q2 FY2026, three months to 2026-06-30$29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure
Gross margin%63.5%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $16.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Revenue: $25.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figure62.5%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $18.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Revenue: $29.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure63.4%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $19.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Revenue: $30.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure65.0%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $20.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $31.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure64.5%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $21.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Revenue: $34.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figure64.1%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $21.7m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Revenue: $33.8m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure63.5%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $20.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Revenue: $31.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure64.8%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $19.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure
Operating margin%6.3%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Revenue: $25.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figure24.4%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $7.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Revenue: $29.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure15.7%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $4.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Revenue: $30.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure10.2%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $31.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure12.5%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Revenue: $34.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figure12.1%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Revenue: $33.8m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure5.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Revenue: $31.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure2.4%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $700.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure
Net margin%7.3%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Revenue: $25.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figure24.6%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $7.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Revenue: $29.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure16.6%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Revenue: $30.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure11.6%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $31.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure13.5%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Revenue: $34.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figure12.2%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $4.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Revenue: $33.8m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure20.1%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Revenue: $31.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure3.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $963.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Revenue: $29.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure
Diluted EPS$ per share0.02Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figurenot reported (Diluted EPS not reported)0.06Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure0.04Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure0.05Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001386570-25-000020.Report this figurenot reported (Diluted EPS not reported)0.07Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001386570-26-000030.Report this figure0.01Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001386570-26-000043.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$129.4mGross margin 64.3%
Diluted EPS$0.20, FY2025
Niagen Bioscience, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m67.4Revenue, FY2021, twelve months to 2021-12-31$67.4m. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-08, accession 0001628280-23-006968.Report this figure72.1Revenue, FY2022, twelve months to 2022-12-31$72.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-06, accession 0001628280-24-009380.Report this figure83.6Revenue, FY2023, twelve months to 2023-12-31$83.6m. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-04, accession 0001628280-25-009774.Report this figure99.6Revenue, FY2024, twelve months to 2024-12-31$99.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure129Revenue, FY2025, twelve months to 2025-12-31$129.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure
Gross margin%61.5%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $41.5m. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-03-08, accession 0001628280-23-006968.Revenue: $67.4m. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-08, accession 0001628280-23-006968.Report this figure59.4%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $42.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-06, accession 0001628280-24-009380.Revenue: $72.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-06, accession 0001628280-24-009380.Report this figure60.8%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $50.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-04, accession 0001628280-25-009774.Revenue: $83.6m. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-04, accession 0001628280-25-009774.Report this figure61.8%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $61.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-04, accession 0001386570-26-000013.Revenue: $99.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure64.3%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $83.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-04, accession 0001386570-26-000013.Revenue: $129.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure
Operating margin%(40.1%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$27.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-08, accession 0001628280-23-006968.Revenue: $67.4m. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-08, accession 0001628280-23-006968.Report this figure(25.9%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-06, accession 0001628280-24-009380.Revenue: $72.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-06, accession 0001628280-24-009380.Report this figure(6.7%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$5.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-04, accession 0001628280-25-009774.Revenue: $83.6m. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-04, accession 0001628280-25-009774.Report this figure7.8%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $7.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-04, accession 0001386570-26-000013.Revenue: $99.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure12.6%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $16.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-04, accession 0001386570-26-000013.Revenue: $129.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure
Net margin%(40.2%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$27.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-08, accession 0001628280-23-006968.Revenue: $67.4m. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-08, accession 0001628280-23-006968.Report this figure(23.0%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$16.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-06, accession 0001628280-24-009380.Revenue: $72.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-06, accession 0001628280-24-009380.Report this figure(5.9%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$4.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-04, accession 0001628280-25-009774.Revenue: $83.6m. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-04, accession 0001628280-25-009774.Report this figure8.6%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $8.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-04, accession 0001386570-26-000013.Revenue: $99.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure13.4%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $17.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-04, accession 0001386570-26-000013.Revenue: $129.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure
Diluted EPS$ per share(0.40)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-08, accession 0001628280-23-006968.Report this figure(0.24)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-06, accession 0001628280-24-009380.Report this figure(0.07)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-04, accession 0001628280-25-009774.Report this figure0.11Diluted EPS, FY2024, twelve months to 2024-12-31$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure0.20Diluted EPS, FY2025, twelve months to 2025-12-31$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-04, accession 0001386570-26-000013.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Niagen Bioscience, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$13.3m4,184,659Added+313,040
SteelPeak Wealth, LLC2026-06-30$11.2m3,500,129Added+127,129
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$6.8m2,147,018Reduced−2,259
Qube Research & Technologies Ltd2026-06-30$5.2m1,625,016Reduced−89,623
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$4.7m1,478,603Added+133,682
UBS Group AG2026-06-30$4.1m1,283,296Reduced−122,235
GOLDMAN SACHS GROUP INC2026-06-30$4.0m1,262,743Added+10,784
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP2026-06-30$3.7m1,171,215Reduced−1,207,222
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$3.7m1,166,233Reduced−55,261
STATE STREET CORP2026-06-30$3.5m1,082,752Reduced−1,813

Recent filings

All 934 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Niagen Bioscience, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0416:04 ET10-QQuarterly reportPeriod 2026-06-300001386570-26-000043
2026-08-0416:03 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001386570-26-000042
2026-06-2916:30 ET8-K5.07 Shareholder vote results0001386570-26-000035
2026-05-0616:01 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001386570-26-000031
2026-05-0616:01 ET10-QQuarterly reportPeriod 2026-03-310001386570-26-000030
2026-04-2916:02 ETDEF 14AProxy statementPeriod 2026-06-240001386570-26-000022
2026-03-1908:34 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001386570-26-000017
2026-03-0416:01 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001386570-26-000014
2026-03-0416:01 ET10-KAnnual reportPeriod 2025-12-310001386570-26-000013
2026-02-2607:02 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001386570-26-000003

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 4, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1386570
Tickers
NAGE
Exchange
Nasdaq
SIC code
2833 Medicinal Chemicals & Botanical Products
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
ChromaDex Corp. (to 2025-03-10); CODY RESOURCES, INC. (to 2008-06-24)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.